Clinical Trials | March 24, 2026
Pfizer and Valneva report promising Phase 3 Lyme disease vaccine results
The company plans to submit the vaccine for regulatory review
The company plans to submit the vaccine for regulatory review
RSM01, a preventive treatment targeting respiratory syncytial virus (RSV), was licensed earlier this month from the Gates Medical Research Institute
The deal also includes upfront licensing fees and milestone-based payments from Lupin to Zydus
The expanded program allows patients to fill prescriptions either at a local pharmacy or through home delivery via LillyDirect
Previously, Arexvy was authorized for adults 60 and older, and for those 50–59 with heightened risk
Under the deal, Hims & Hers will offer patients access to FDA-approved versions of Ozempic and Wegovy at the same self-pay prices available through other telehealth platforms
The two companies will collaborate to evaluate Hopewell’s ttLNPs for clinical applications
Starting January 1, 2027, Lilly’s Zepbound (tirzepatide), Mounjaro (tirzepatide), and orforglipron, if approved, will be available through participating Medicare Part D plans
The 6th Edition NABH framework places strong emphasis on patient safety protocols, robust clinical governance, risk management systems
Moderna will appeal to the Federal Circuit to assert that its government-contractor immunity limits liability under federal law
Subscribe To Our Newsletter & Stay Updated
